专利检索 ap:("Jean-Damien Charrier" OR "Somhairle MacCormick" OR "Pierre-Henri Storck" OR "Joanne Pinder" OR "Michael Edward O'Donnell" OR "Ronald Marcellus Alphonsus Knegtel" OR "Stephen Clinton Young" OR "Philip Michael Reaper" OR "Steven John Durrant" OR "Heather Clare Twin" OR "Christopher John Davis") AND inv:"Jean-Damien Charrier" 第 3 页

21.

发明申请
COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE 有权
标题翻译：化合物作为ATR激酶的抑制剂有用

公开(公告)号：US20120177748A1

公开(公告)日：2012-07-12

申请号：US13106178

申请日：2011-05-12

申请人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Philip Michael Reaper

发明人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Philip Michael Reaper

IPC分类号： A61K31/444 , C07D413/04 , A61P35/00 , C07D413/14 , A61K31/551 , A61K33/24 , C07D401/04 , A61K31/4439

CPC分类号： C07D413/14 , C07D213/82 , C07D413/04

摘要： The present invention relates to pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula III: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡啶化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式III：其中变量如本文所定义。

22.

发明申请
COMPOUNDS USEFUL AS INHIBITORS OF ATR KINASE 有权
标题翻译：化合物作为ATR激酶的抑制剂有用

公开(公告)号：US20120035407A1

公开(公告)日：2012-02-09

申请号：US13106173

申请日：2011-05-12

申请人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Michael O'Donnell , Philip Michael Reaper

发明人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Michael O'Donnell , Philip Michael Reaper

IPC分类号： A61N5/00 , A61K31/497 , C07D403/04 , C07D401/14 , C07D403/14 , A61P35/00 , A61K31/5377 , C07D241/28 , A61K31/4965 , C07D413/04 , C07D401/12 , C07D405/14 , C07D413/14

CPC分类号： C07D403/04 , C07D241/24 , C07D403/12 , C07D417/04

摘要： The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula II: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式II：其中变量如本文所定义。

23.

发明授权
Compounds useful as inhibitors of ATR kinase 有权
标题翻译：可用作ATR激酶抑制剂的化合物

公开(公告)号：US09334244B2

公开(公告)日：2016-05-10

申请号：US13106184

申请日：2011-05-12

申请人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Anisa Nizarali Virani , Philip Michael Reaper

发明人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Anisa Nizarali Virani , Philip Michael Reaper

IPC分类号： C07D241/06 , C07D413/04 , C07D239/46

CPC分类号： A61K31/4965 , A61K31/497 , A61K33/24 , C07D239/46 , C07D241/24 , C07D413/04

摘要： The present invention relates to pyrazine and pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula IV: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪和吡啶化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式IV：其中变量如本文所定义。

24.

发明授权
Compounds useful as inhibitors of ATR kinase 有权
标题翻译：可用作ATR激酶抑制剂的化合物

公开(公告)号：US09096584B2

公开(公告)日：2015-08-04

申请号：US13106178

申请日：2011-05-12

申请人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Philip Michael Reaper

发明人： Jean-Damien Charrier , Steven John Durrant , Ronald Marcellus Alphonsus Knegtel , Philip Michael Reaper

IPC分类号： C07D413/14 , A61K31/4245 , C07D213/82 , C07D413/04

CPC分类号： C07D413/14 , C07D213/82 , C07D413/04

摘要： The present invention relates to pyridine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula III: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡啶化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式III：其中变量如本文所定义。

25.

发明授权
Pyrazin-2-amines useful as inhibitors of ATR kinase 有权
标题翻译：吡嗪-2-胺可用作ATR激酶的抑制剂

公开(公告)号：US08841308B2

公开(公告)日：2014-09-23

申请号：US12642447

申请日：2009-12-18

申请人： Jean-Damien Charrier , David Kay , Ronald Knegtel , Somhairle MacCormick , Michael O'Donnell , Joanne Pinder , Philip Michael Reaper

发明人： Jean-Damien Charrier , David Kay , Ronald Knegtel , Somhairle MacCormick , Michael O'Donnell , Joanne Pinder , Philip Michael Reaper

IPC分类号： A61K31/4965

CPC分类号： C07D413/14 , A61P35/00 , C07D241/28 , C07D401/04 , C07D401/10 , C07D401/14 , C07D403/04 , C07D403/10 , C07D403/12 , C07D403/14 , C07D405/04 , C07D405/12 , C07D405/14 , C07D409/04 , C07D409/14 , C07D413/04 , C07D413/12 , C07D417/04 , C07D417/12 , C07D417/14 , C07D471/04

摘要： The present invention relates to pyrazine compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的吡嗪化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式I：其中变量如本文所定义。

26.

发明申请
Compounds Useful as Inhibitors of ATR Kinase 有权
标题翻译：可用作ATR激酶抑制剂的化合物

公开(公告)号：US20130089625A1

公开(公告)日：2013-04-11

申请号：US13631732

申请日：2012-09-28

申请人： Jean-Damien Charrier , Pierre-Henri Storck , John Studley , Francoise Yvonne Theodora Marie Pierard , Steven John Durrant , Benjamin Joseph Littler , Paul Angell , Robert Michael Hughes , David Andrew Siesel , Armando Urbina , Carl Zwicker , Nicholas LoConte , Timothy Barder

发明人： Jean-Damien Charrier , Pierre-Henri Storck , John Studley , Francoise Yvonne Theodora Marie Pierard , Steven John Durrant , Benjamin Joseph Littler , Paul Angell , Robert Michael Hughes , David Andrew Siesel , Armando Urbina , Carl Zwicker , Nicholas LoConte , Timothy Barder

IPC分类号： C07D413/14 , A61K45/06 , A61N5/10 , A61K31/4745 , A61K31/7068 , A61K31/497 , A61K33/24

CPC分类号： C07D413/14 , A61K31/4745 , A61K31/497 , A61K31/7068 , A61K33/24 , A61K45/06 , A61N5/10

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; solid forms of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I-1: wherein the variables are as defined herein.Additionally, the compounds of this invention have formula II: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined herein.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 固体形式的本发明化合物; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式I-1：其中变量如本文所定义。此外，本发明的化合物具有式II：或其药学上可接受的盐，其中变量如本文所定义。

27.

发明申请
Compounds Useful as Inhibitors of ATR Kinase 失效
标题翻译：可用作ATR激酶抑制剂的化合物

公开(公告)号：US20130089624A1

公开(公告)日：2013-04-11

申请号：US13631730

申请日：2012-09-28

申请人： Jean-Damien Charrier , Stephen Clinton Young , Christopher John Davis , John Studley

发明人： Jean-Damien Charrier , Stephen Clinton Young , Christopher John Davis , John Studley

IPC分类号： C07D413/14 , A61K33/24 , C07D267/10 , C07D413/10 , C07D413/04 , A61K31/5377 , C07D265/30

CPC分类号： A61K31/5377 , A61K33/24 , C07D265/30 , C07D267/10 , C07D401/04 , C07D413/04 , C07D413/10 , C07D413/14

摘要： The present invention relates to compounds useful as inhibitors of ATR protein kinase. The invention also relates to pharmaceutically acceptable compositions comprising the compounds of this invention; methods of treating of various diseases, disorders, and conditions using the compounds of this invention; processes for preparing the compounds of this invention; intermediates for the preparation of the compounds of this invention; and methods of using the compounds in in vitro applications, such as the study of kinases in biological and pathological phenomena; the study of intracellular signal transduction pathways mediated by such kinases; and the comparative evaluation of new kinase inhibitors.The compounds of this invention have formula I: wherein the variables are as defined herein.Additionally, the present invention also relates to novel processes for the production of various morpoholine based intermediates.

摘要翻译： 本发明涉及可用作ATR蛋白激酶抑制剂的化合物。本发明还涉及包含本发明化合物的药学上可接受的组合物; 使用本发明化合物治疗各种疾病，病症和病症的方法; 制备本发明化合物的方法; 用于制备本发明化合物的中间体; 以及在体外应用中使用化合物的方法，如生物和病理现象中激酶的研究; 由这种激酶介导的细胞内信号转导途径的研究; 和新型激酶抑制剂的比较评估。本发明的化合物具有式I：其中变量如本文所定义。此外，本发明还涉及用于生产各种基于morpoholine的中间体的新方法。